Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts

IF 3.3 4区医学 Q2 HEMATOLOGY Hematological Oncology Pub Date : 2025-02-03 DOI:10.1002/hon.70043

Gaixiang Xu, Xingnong Ye, Yudi Zhang, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Yanling Ren, Lingxu Jiang, Jian Huang, Haitao Meng, Wenyuan Mai, Wenjuan Yu, Jie Jin, Hongyan Tong

{"title":"Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased Blasts","authors":"Gaixiang Xu, Xingnong Ye, Yudi Zhang, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Yanling Ren, Lingxu Jiang, Jian Huang, Haitao Meng, Wenyuan Mai, Wenjuan Yu, Jie Jin, Hongyan Tong","doi":"10.1002/hon.70043","DOIUrl":null,"url":null,"abstract":"<div>\n \n This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate-to-severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression-free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS-EB) subtypes, individuals with MF2-3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0-1. However, individuals with MF0-1 and MF2-3 showed similar OS and PFS rates among the patients with the MDS non-excess blast (MDS-nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS-f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS-IB) subtypes. Our study reveals the unique features of patients with MDS-MF2-3 and validates the refinements made in the 5th edition of the WHO proposal.\n </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 2","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This study, including 412 patients newly diagnosed with myelodysplastic neoplasm (MDS), investigated the clinical, molecular, and prognostic features of MDS with moderate-to-severe bone marrow fibrosis (MF). Among the patients with MDS, 347 (84%) had MF grade 0–1 (MF0–1), and 65 (16%) had MF grade 2–3 (MF2–3). Patients with MDS with MF2–3 showed similar overall survival (OS) (16.6 vs. 21.3 months; p = 0.34) but demonstrated inferior progression-free survival (PFS) (6.6 vs. 15.2 months; p = 0.02) and a higher risk of leukemia transformation (35.4 vs. 16.4%; p < 0.001) compared to those with MF0–1. In the MDS with excess blast (MDS-EB) subtypes, individuals with MF2-3 exhibited shorter OS (4.8 vs. 11.7 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than those in patients with MF0-1. However, individuals with MF0-1 and MF2-3 showed similar OS and PFS rates among the patients with the MDS non-excess blast (MDS-nonEB) subtypes. Additionally, we reclassified the patients with MDS according to the 2022 World Health Organization (WHO) classification. Patients with MDS with fibrosis (MDS-f) had a shorter OS (5.6 vs. 13.8 months; p = 0.01) and PFS (3.1 vs. 7.9 months; p = 0.006) than MDS with increased blasts (MDS-IB) subtypes. Our study reveals the unique features of patients with MDS-MF2-3 and validates the refinements made in the 5th edition of the WHO proposal.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.